

Benjamin P Kleinstiver

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5014177/publications.pdf>

Version: 2024-02-01

46
papers

9,148
citations

293460

24
h-index

242451

47
g-index

63
all docs

63
docs citations

63
times ranked

10370
citing authors

#	ARTICLE	IF	CITATIONS
1	High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. <i>Nature</i> , 2016, 529, 490-495.	13.7	2,126
2	Engineered CRISPR-Cas9 nucleases with altered PAM specificities. <i>Nature</i> , 2015, 523, 481-485.	13.7	1,388
3	Enhanced proofreading governs CRISPR-Cas9 targeting accuracy. <i>Nature</i> , 2017, 550, 407-410.	13.7	901
4	Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants. <i>Science</i> , 2020, 368, 290-296.	6.0	714
5	Genome-wide specificities of CRISPR-Cas Cpf1 nucleases in human cells. <i>Nature Biotechnology</i> , 2016, 34, 869-874.	9.4	566
6	Broadening the targeting range of <i>Staphylococcus aureus</i> CRISPR-Cas9 by modifying PAM recognition. <i>Nature Biotechnology</i> , 2015, 33, 1293-1298.	9.4	511
7	Engineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing. <i>Nature Biotechnology</i> , 2019, 37, 276-282.	9.4	439
8	High levels of AAV vector integration into CRISPR-induced DNA breaks. <i>Nature Communications</i> , 2019, 10, 4439.	5.8	257
9	Prediction of off-target activities for the end-to-end design of CRISPR guide RNAs. <i>Nature Biomedical Engineering</i> , 2018, 2, 38-47.	11.6	230
10	Discovery of widespread type I and type V CRISPR-Cas inhibitors. <i>Science</i> , 2018, 362, 240-242.	6.0	214
11	Activities and specificities of CRISPR-Cas9 and Cas12a nucleases for targeted mutagenesis in maize. <i>Plant Biotechnology Journal</i> , 2019, 17, 362-372.	4.1	192
12	Inducible and multiplex gene regulation using CRISPR-Cpf1-based transcription factors. <i>Nature Methods</i> , 2017, 14, 1163-1166.	9.0	170
13	Astrocytic interleukin-3 programs microglia and limits Alzheimer's disease. <i>Nature</i> , 2021, 595, 701-706.	13.7	157
14	Allele-specific gene editing prevents deafness in a model of dominant progressive hearing loss. <i>Nature Medicine</i> , 2019, 25, 1123-1130.	15.2	149
15	Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma. <i>Cancer Discovery</i> , 2016, 6, 727-739.	7.7	126
16	CRISPR/Cas9 Mediated Disruption of the Swedish APP Allele as a Therapeutic Approach for Early-Onset Alzheimer's Disease. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 11, 429-440.	2.3	116
17	Allele-Specific CRISPR-Cas9 Genome Editing of the Single-Base P23H Mutation for Rhodopsin-Associated Dominant Retinitis Pigmentosa. <i>CRISPR Journal</i> , 2018, 1, 55-64.	1.4	96
18	Optimization of AsCas12a for combinatorial genetic screens in human cells. <i>Nature Biotechnology</i> , 2021, 39, 94-104.	9.4	96

#	ARTICLE	IF	CITATIONS
19	Broad-spectrum anti-CRISPR proteins facilitate horizontal gene transfer. <i>Nature Microbiology</i> , 2020, 5, 620-629.	5.9	79
20	Hypoxia drives transient site-specific copy gain and drug-resistant gene expression. <i>Genes and Development</i> , 2015, 29, 1018-1031.	2.7	72
21	Listeria Phages Induce Cas9 Degradation to Protect Lysogenic Genomes. <i>Cell Host and Microbe</i> , 2020, 28, 31-40.e9.	5.1	54
22	Monomeric site-specific nucleases for genome editing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 8061-8066.	3.3	52
23	Enhanced homology-directed repair for highly efficient gene editing in hematopoietic stem/progenitor cells. <i>Blood</i> , 2021, 137, 2598-2608.	0.6	51
24	NNT mediates redox-dependent pigmentation via a UVB- and MITF-independent mechanism. <i>Cell</i> , 2021, 184, 4268-4283.e20.	13.5	35
25	Whole-genome sequencing association analysis of quantitative red blood cell phenotypes: The NHLBI TOPMed program. <i>American Journal of Human Genetics</i> , 2021, 108, 874-893.	2.6	28
26	Genome editing in animals with minimal PAM CRISPR-Cas9 enzymes. <i>Nature Communications</i> , 2022, 13, 2601.	5.8	24
27	The I-TevI Nuclease and Linker Domains Contribute to the Specificity of Monomeric TALENs. <i>G3: Genes, Genomes, Genetics</i> , 2014, 4, 1155-1165.	0.8	23
28	Scalable characterization of the PAM requirements of CRISPR-Cas enzymes using HT-PAMDA. <i>Nature Protocols</i> , 2021, 16, 1511-1547.	5.5	23
29	In vivo engineering of lymphocytes after systemic exosome-associated AAV delivery. <i>Scientific Reports</i> , 2020, 10, 4544.	1.6	20
30	CRISPR-targeted <i>MAGT1</i> insertion restores XMEN patient hematopoietic stem cells and lymphocytes. <i>Blood</i> , 2021, 138, 2768-2780.	0.6	20
31	Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway. <i>Oncotarget</i> , 2017, 8, 43733-43751.	0.8	20
32	Temporal and Spatial Post-Transcriptional Regulation of Zebrafish <i>tie1</i> mRNA by Long Noncoding RNA During Brain Vascular Assembly. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 1562-1575.	1.1	19
33	A unified genetic, computational and experimental framework identifies functionally relevant residues of the homing endonuclease I-Bmol. <i>Nucleic Acids Research</i> , 2010, 38, 2411-2427.	6.5	17
34	Strand-specific Contacts and Divalent Metal Ion Regulate Double-strand Break Formation by the GIY-YIG Homing Endonuclease I-Bmol. <i>Journal of Molecular Biology</i> , 2007, 374, 306-321.	2.0	15
35	CRISPR-Cas knockout of miR21 reduces glioma growth. <i>Molecular Therapy - Oncolytics</i> , 2022, 25, 121-136.	2.0	14
36	The monomeric GIY-YIG homing endonuclease I-Bmol uses a molecular anchor and a flexible tether to sequentially nick DNA. <i>Nucleic Acids Research</i> , 2013, 41, 5413-5427.	6.5	13

#	ARTICLE	IF	CITATIONS
37	Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources. , 2020, 8, e000990.		13
38	Mutant Allele-Specific CRISPR Disruption in DYT1 Dystonia Fibroblasts Restores Cell Function. Molecular Therapy - Nucleic Acids, 2020, 21, 1-12.	2.3	8
39	enAsCas12a Enables CRISPR-Directed Evolution to Screen for Functional Drug Resistance Mutations in Sequences Inaccessible to SpCas9. Molecular Therapy, 2021, 29, 208-224.	3.7	8
40	Divalent Metal Ion Differentially Regulates the Sequential Nicking Reactions of the GIY-YIG Homing Endonuclease I-Bmol. PLoS ONE, 2011, 6, e23804.	1.1	7
41	Voices in methods development. Nature Methods, 2019, 16, 945-951.	9.0	5
42	Lack of Cas13a inhibition by anti-CRISPR proteins from Leptotrichia prophages. Molecular Cell, 2022, 82, 2161-2166.e3.	4.5	4
43	Making the cut with PAMless CRISPR-Cas enzymes. Trends in Genetics, 2021, 37, 1053-1055.	2.9	3
44	Plant genome editing branches out. Nature Plants, 2021, 7, 4-5.	4.7	3
45	Estimating the evidence of selection and the reliability of inference in unigenic evolution. Algorithms for Molecular Biology, 2010, 5, 35.	0.3	1
46	Rapid Screening of Endonuclease Target Site Preference Using a Modified Bacterial Two-Plasmid Selection. Methods in Molecular Biology, 2014, 1123, 97-104.	0.4	1